Beroni Group Limited

NSX:BTG ISIN:AU000000BTG8

Beroni GroupBeroni Group (NSX:BTG) (OTCMKTS:BNIGF) is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. To learn more about Beroni, please visit www.beronigroup.com.

 
 

News

Beroni Group Limited (NSX:BTG) Enters into Convertible Loans

🕔11/9/2023 8:49:00 AM 1256

Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into an unsecured and interest free convertible loan agreement with a group of investors for a principal loan amount of US$410,397.

Read Full Article

Beroni Group Limited (NSX:BTG) Enters Into Convertible Loan With Investor

🕔9/22/2023 12:41:00 PM 928

Beroni Group Limited (NSX:BTG) Beroni Enters Into Convertible Loan With Investor

Read Full Article

Beroni Group Limited (NSX:BTG) Enters Into Convertible Loans With Investors

🕔4/20/2023 7:19:00 AM 1875

Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG) advises that it has entered into unsecured and interest free convertible loan agreements with two investors for an aggregate principal loan amount of US$291,545.

Read Full Article

Beroni Group Limited (NSX:BTG) Advances R&D of Enhanced COVID-19 Antigen RTK

🕔2/8/2023 4:39:00 PM 2633

Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, announced that its enhanced COVID-19 Antigen Rapid Test Kit - Colloidal Gold Method has been undergoing clinical trial in China, for eventual application to the National Medical Product Administration.

Read Full Article

Beroni Group Limited (NSX:BTG) Antigen Rapid Test Kit Received CE Certification

🕔6/1/2022 9:05:00 AM 2090

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) announced that it has received notification that its latest enhanced COVID-19 Antigen Rapid Test Kit has complied with the applicable essential requirements of the council directive 98/79/EEC in vitro diagnostics as amended.

Read Full Article

Beroni Group Limited (NSX:BTG) Issues US$500K of Convertible Notes

🕔1/31/2022 9:11:00 AM 1906

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) today announced that it has raised US$500K from the issue of convertible notes to an investor in China.

Read Full Article

Beroni Group Limited (NSX:BTG) New R&D Centre in High-Tech Hub in Zhuhai, China

🕔1/31/2022 9:11:00 AM 2171

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) is pleased to announce that it has signed a contract to build a new Research & Development centre in the Zhuhai National High-Tech Industrial Development Zone in China.

Read Full Article

Beroni Group Limited (NSX:BTG) US$1.07M COVID-19 Antigen Test Kits Order from Japan

🕔11/18/2021 2:15:00 PM 3340

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG) announced that it has received part payment of a US$1.07M (JPY117.5M) order for its SARS-CoV-2 Antigen Test Kit from a Japanese pharmaceutical company based in Tokyo.

Read Full Article

Beroni Group Limited (NSX:BTG) Published Article on the FEBS Journal

🕔10/28/2021 4:08:00 PM 4058

Beroni Group Limited (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that its article has been accepted for publication and undergone full review in the FEBS Journal.

Read Full Article

Beroni Group Limited (NSX:BTG) Approval for R&D Rebate for Anti-Cancer Drug PENAO

🕔9/9/2021 4:05:00 PM 3374

Beroni Group (OTCMKTS:BNIGF) (NSX:BTG), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure.

Read Full Article
###

15,374 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 19) (Last 30 Days: 240) (Since Published: 15374) 

Company Data

    Headquarters
  • Level 16, 175 Pitt Street
    Sydney, NSW 2000
    Australia
  • Telephone
  • +61-2-9159-1827 
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Pharmaceutical 
  • Homepage
  • www.beronigroup.com

Company Reports